PDCD1 and pneumonitis: Generally, the toxicity associated with PD-1/L1 agents is reported to be less than that with anti-CTLA-4 antibodies, although certain organ-specific side effects, such as pneumonitis, have only appeared under PD-1 blockade therapy [66, 67].